Výsledky vyhledávání

Akademický článek

Empagliflozin improved systolic blood pressure, endothelial dysfunction and heart remodeling in the metabolic syndrome ZSF1 rat

Autor: Sin-Hee Park, Muhammad Akmal Farooq, Sébastien Gaertner, Christophe Bruckert, Abdul Wahid Qureshi, Hyun-Ho Lee, Djamel Benrahla, Brigitte Pollet, Dominique Stephan, Patrick Ohlmann, Jean-Marc Lessinger, Eric Mayoux, Cyril Auger, Olivier Morel, Valérie B. Schini-Kerth

Publikováno v: Cardiovascular Diabetology, Vol 19, Iss 1, Pp 1-14 (2020)

Abstract Background Empagliflozin (empa), a selective sodium–glucose cotransporter (SGLT)2 inhibitor, reduced cardiovascular mortality and hospitalization for heart failure in patients with type 2 diabetes at high cardiovascular risk independent of

Externí odkaz: https://doaj.org/article/1a781d74075649d3919486e0c679b5b4

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

SGLT2 is not expressed in pancreatic α- and β-cells, and its inhibition does not directly affect glucagon and insulin secretion in rodents and humans

Publikováno v: Molecular Metabolism, Vol 42, Iss , Pp 101071- (2020)

Objective: Sodium-glucose cotransporter 2 (SGLT2) inhibitors (SGLT2i), or gliflozins, are anti-diabetic drugs that lower glycemia by promoting glucosuria, but they also stimulate endogenous glucose and ketone body production. The likely causes of the

Externí odkaz: https://doaj.org/article/21bfada24dc04976b5da4c463b456525

Zobrazit plný text záznamu

Akademický článek

Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury

Autor: Annayya R. Aroor, Nitin A. Das, Andrea J. Carpenter, Javad Habibi, Guanghong Jia, Francisco I. Ramirez-Perez, Luis Martinez-Lemus, Camila M. Manrique-Acevedo, Melvin R. Hayden, Cornel Duta, Ravi Nistala, Eric Mayoux, Jaume Padilla, Bysani Chandrasekar, Vincent G. DeMarco

Publikováno v: Cardiovascular Diabetology, Vol 17, Iss 1, Pp 1-14 (2018)

Abstract Background Arterial stiffness is emerging as an independent risk factor for the development of chronic kidney disease. The sodium glucose co-transporter 2 (SGLT2) inhibitors, which lower serum glucose by inhibiting SGLT2-mediated glucose rea

Externí odkaz: https://doaj.org/article/762775bbe4d347228d8b8580356663b2

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats

Autor: Sebastian Steven, Matthias Oelze, Alina Hanf, Swenja Kröller-Schön, Fatemeh Kashani, Siyer Roohani, Philipp Welschof, Maximilian Kopp, Ute Gödtel-Armbrust, Ning Xia, Huige Li, Eberhard Schulz, Karl J. Lackner, Leszek Wojnowski, Serge P. Bottari, Philip Wenzel, Eric Mayoux, Thomas Münzel, Andreas Daiber

Publikováno v: Redox Biology, Vol 13, Iss C, Pp 370-385 (2017)

Hyperglycemia associated with inflammation and oxidative stress is a major cause of vascular dysfunction and cardiovascular disease in diabetes. Recent data reports that a selective sodium-glucose co-transporter 2 inhibitor (SGLT2i), empagliflozin (J

Externí odkaz: https://doaj.org/article/7e8a8df60a79492ab7f5ea227c2d7c8b

Zobrazit plný text záznamu

Akademický článek

SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice

Autor: Liang Xu, Naoto Nagata, Mayumi Nagashimada, Fen Zhuge, Yinhua Ni, Guanliang Chen, Eric Mayoux, Shuichi Kaneko, Tsuguhito Ota

Publikováno v: EBioMedicine, Vol 20, Iss C, Pp 137-149 (2017)

Sodium-glucose cotransporter (SGLT) 2 inhibitors increase urinary glucose excretion (UGE), leading to blood glucose reductions and weight loss. However, the impacts of SGLT2 inhibition on energy homeostasis and obesity-induced insulin resistance are

Externí odkaz: https://doaj.org/article/ec13e591e3f244278f0b38479ba3d610

Zobrazit plný text záznamu

Akademický článek

The Effects of Empagliflozin, an SGLT2 Inhibitor, on Pancreatic β-Cell Mass and Glucose Homeostasis in Type 1 Diabetes.

Autor: Sam Tsz Wai Cheng, Lihua Chen, Stephen Yu Ting Li, Eric Mayoux, Po Sing Leung

Publikováno v: PLoS ONE, Vol 11, Iss 1, p e0147391 (2016)

The novel sodium glucose co-transporter 2 (SGLT2) inhibitor empagliflozin has recently been reported to improve glycemic control in streptozotocin-induced type 1 diabetic rats in an insulin-independent manner, via an increase in urinary glucose outpu

Externí odkaz: https://doaj.org/article/32ea288b86ed4cb2989b7cc7a58f665c

Zobrazit plný text záznamu

Akademický článek

The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity.

Autor: Matthias Oelze, Swenja Kröller-Schön, Philipp Welschof, Thomas Jansen, Michael Hausding, Yuliya Mikhed, Paul Stamm, Michael Mader, Elena Zinßius, Saule Agdauletova, Anna Gottschlich, Sebastian Steven, Eberhard Schulz, Serge P Bottari, Eric Mayoux, Thomas Münzel, Andreas Daiber

Publikováno v: PLoS ONE, Vol 9, Iss 11, p e112394 (2014)

OBJECTIVE: In diabetes, vascular dysfunction is characterized by impaired endothelial function due to increased oxidative stress. Empagliflozin, as a selective sodium-glucose co-transporter 2 inhibitor (SGLT2i), offers a novel approach for the treatm

Externí odkaz: https://doaj.org/article/89298fb08472410b8081d15236c79a94

Zobrazit plný text záznamu

SGLT2 is not expressed in pancreatic α- and β-cells, and its inhibition does not directly affect glucagon and insulin secretion in rodents and humans

Publikováno v: Molecular Metabolism
Molecular metabolism, vol. 42, pp. 101071
Molecular metabolism
Molecular metabolism, Elsevier, 2020, 42, pp.101071. ⟨10.1016/j.molmet.2020.101071⟩
Molecular Metabolism (2020) P. 101071
Molecular Metabolism, Vol 42, Iss, Pp 101071-(2020)

Objective Sodium-glucose cotransporter 2 (SGLT2) inhibitors (SGLT2i), or gliflozins, are anti-diabetic drugs that lower glycemia by promoting glucosuria, but they also stimulate endogenous glucose and ketone body production. The likely causes of thes

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::13201cec4df0020051e57406d53b494a
https://pubmed.ncbi.nlm.nih.gov/32896668

Zobrazit plný text záznamu

1109-P: Blood Pressure (BP) Lowering Effect of Empagliflozin Is Related to Decreased L-Arginine Clearance in Diabetic Rats

Autor: Michael Mark, Eric Mayoux, Daniel Veyel, Michael P. Pieper, Bartlomiej Krawczyk, Sonia Khemais-Benkhiat, Valérie B. Schini-Kerth

Publikováno v: Diabetes. 69

Introduction: The availability of L-arginine is the rate-limiting factor in Nitric Oxide (NO) synthesis, a potent vasodilatory factor. L-arginine plasma levels are blunted in diabetes, thus L-arginine supplementation decreases BP in animal diabetic m

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6fb4ade2eabca00210473dbf0e14ca09
https://doi.org/10.2337/db20-1109-p

Zobrazit plný text záznamu

Empagliflozin improved systolic blood pressure, endothelial dysfunction and heart remodeling in the metabolic syndrome ZSF1 rat

Autor: A.W. Qureshi, Brigitte Pollet, Valérie B. Schini-Kerth, Hyun-Ho Lee, Djamel Benrahla, Jean-Marc Lessinger, Christophe Bruckert, Muhammad Akmal Farooq, Dominique Stephan, Eric Mayoux, Sin-Hee Park, Sébastien Gaertner, Cyril Auger, Patrick Ohlmann, Olivier Morel

Publikováno v: Cardiovascular Diabetology
Cardiovascular Diabetology, 2020, 19 (1), ⟨10.1186/s12933-020-00997-7⟩
Cardiovascular Diabetology, Vol 19, Iss 1, Pp 1-14 (2020)
Cardiovascular Diabetology, BioMed Central, 2020, 19 (1), ⟨10.1186/s12933-020-00997-7⟩

BackgroundEmpagliflozin (empa), a selective sodium–glucose cotransporter (SGLT)2 inhibitor, reduced cardiovascular mortality and hospitalization for heart failure in patients with type 2 diabetes at high cardiovascular risk independent of glycemic

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fbcfcb9d336fd2d003fa21ff2dd41ed1
https://cnrs.hal.science/hal-03033762

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání